Merck Completes Cidara Takeover to Add a Long-Acting Flu Antiviral

More like this

• Business10/04/2026@EconDesk

  AbbVie Completes Its Acquisition of Allergan

  1 North Waukegan Road, North Chicago, Illinois, United StatesAbbVie

  

  Starts 05/08/2020CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins81% CONFIDENCEOverall confidence: 81%How well the pin's source and references back up its dates.Weighted average of how firmly 3 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better6.4 years agoAbbVie's^[1][2] release 'AbbVie Inc. Completes Acquisition of Allergan plc' is dated May 08, 2020 and says the scheme 'became effective earlier today, May 8, 2020'.

  On 8 May 2020 AbbVie completed its acquisition of Irish drugmaker Allergan plc through an Irish scheme of arrangement, adding the Botox, Juvederm and eye-care businesses to its immunology and neuroscience portfolio.

  0.69

  00
• Business10/04/2026@EconDesk

  Merck to Buy Terns for US$6.7 Billion for a Leukemia Drug

  126 East Lincoln Avenue, Rahway, New Jersey, United StatesMerck & Co.

  

  Starts 03/25/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins83% CONFIDENCEOverall confidence: 83%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better195 days agoThe Merck and Terns news release (SEC^[1] Exhibit 99.1) is datelined 'RAHWAY, N.J., and FOSTER CITY, Calif., March 25, 2026' and Pharmaceutical Technology reported it the same day.

  On 25 March 2026 Merck agreed to acquire Terns Pharmaceuticals for US$53.00 per share in cash, about US$6.7 billion, to get TERN-701, an oral allosteric BCR::ABL1 inhibitor for chronic myeloid leukemia.

  $6.7B

  0.66

  00
• Health10/04/2026@HealthDesk

  FDA Approves Merck's Lipfendra, the First Oral PCSK9 Inhibitor

  126 East Lincoln Avenue, Rahway, New Jersey, United StatesMerck & Co.

  

  Starts 07/16/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins83% CONFIDENCEOverall confidence: 83%How well the pin's source and references back up its dates.Weighted average of how firmly 5 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better82 days agoMerck's^[1][2] news release is dated July 16, 2026 and says the FDA 'has approved LIPFENDRA (enlicitide) tablets 20 mg'; Practical Neurology^[4] and the Family Heart^[5] Foundation report the same.

  On 16 July 2026 the FDA approved Merck's Lipfendra (enlicitide), a once-daily 20 mg tablet and the first oral PCSK9 inhibitor, to lower LDL cholesterol in adults with hypercholesterolemia.

  0.66

  00
• Business10/04/2026@HealthDesk

  Sanofi Completes Its US$2.2 Billion Purchase of Dynavax

  46-48 Avenue de la Grande Armée, Paris, FranceSanofi

  

  Starts 02/10/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins86% CONFIDENCEOverall confidence: 86%How well the pin's source and references back up its dates.Weighted average of how firmly 3 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better238 days agoSanofi's^[1] press release is dated February 10, 2026 and says it accepted tendered shares for payment and completed the merger that day, after the tender offer expired on 9 February.

  On 10 February 2026 Sanofi completed the acquisition of vaccine maker Dynavax at US$15.50 a share in cash, adding the two-dose hepatitis B vaccine Heplisav-B and a shingles vaccine candidate.

  $2.2B

  0.64

  00
• Health09/20/2026@HealthDesk

  MK-8527's Phase 3 Trial in Human Immunodeficiency Virus Reads Out

  Merck & Co.Rahway, United States

  Starts 10/18/2027ESTIMATEDDate confidence: ESTIMATEDA target, not a fixed dateHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all ESTIMATED pins50% CONFIDENCEOverall confidence: 50%How well the pin's source and references back up its dates.Weighted average of how firmly 1 reference, the source included, supports the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins from 50% to 74% confidencein 1.0 yearsClinicalTrials.gov^[1] lists 2027-10-18 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

  Merck & Co.'s phase 3 trial of MK-8527 in human immunodeficiency virus reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,580 participants. Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection.

  0.64

  10
• Health09/23/2026@HealthDesk

  Lilly Agrees to Buy Three Vaccine Developers for Up to $3.83 Billion

  Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United StatesEli Lilly

  

  Starts 05/26/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins87% CONFIDENCEOverall confidence: 87%How well the pin's source and references back up its dates.Weighted average of how firmly 5 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better133 days agoLilly's release is datelined "INDIANAPOLIS, May 26, 2026" and says Lilly "today announced agreements to acquire three companies".^[1]

  Lilly moves into infectious disease by agreeing to buy Curevo (shingles), LimmaTech Biologics (staph and other bacteria) and Vaccine Company (Epstein-Barr virus) for up to $3.83 billion combined in cash.

  $3.8B

  0.64

  30
• Health09/20/2026@HealthDesk

  Tozorakimab's Phase 3 Trial in Viral Lung Infection and Acute Respiratory Failure Reads Out

  AstraZenecaCambridge, United Kingdom

  Starts 11/04/2027ESTIMATEDDate confidence: ESTIMATEDA target, not a fixed dateHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all ESTIMATED pins50% CONFIDENCEOverall confidence: 50%How well the pin's source and references back up its dates.Weighted average of how firmly 1 reference, the source included, supports the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins from 50% to 74% confidencein 1.1 yearsClinicalTrials.gov^[1] lists 2027-11-04 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

  AstraZeneca's phase 3 trial of Tozorakimab in viral lung infection and acute respiratory failure reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 3,527 participants. The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.

  0.63

  00
• Health09/23/2026@HealthDesk

  Lilly Agrees to Acquire Merida Biosciences for Up to $2.875 Billion

  Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United StatesEli Lilly

  

  Starts 08/31/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins88% CONFIDENCEOverall confidence: 88%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better36 days agoThe release is datelined "INDIANAPOLIS and CAMBRIDGE, Mass., Aug. 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Merida".^[1]

  Lilly agrees to buy Merida Biosciences, whose Phase 1 MER511 is built to destroy the autoantibodies behind Graves' disease and thyroid eye disease, for up to $2.875 billion in cash.

  $2.9B

  0.63

  00
• Business10/04/2026@HealthDesk

  Sanofi and Regeneron Expand Their Alliance With US$1 Billion Upfront

  46-48 Avenue de la Grande Armée, Paris, FranceSanofi

  

  Starts 10/01/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins86% CONFIDENCEOverall confidence: 86%How well the pin's source and references back up its dates.Weighted average of how firmly 3 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better5 days agoSanofi's^[1] press release is datelined "Paris and Tarrytown, NY, October 1, 2026" and the same release was furnished to the SEC^[3].

  On 1 October 2026 Sanofi and Regeneron announced they will co-develop four new long-acting immunology antibodies; Regeneron receives US$1 billion upfront and up to US$7 billion more in milestones.

  $1B

  0.62

  00
• Automotive09/25/2026@LuxuryDesk

  CYVN Holdings Completes Its Buyout of McLaren Automotive

  McLaren Technology Centre, Durnford Farm, Woking, Surrey, England, GU21 4YH, United KingdomMcLaren Automotive

  

  Starts 04/04/2025ESTIMATEDDate confidence: ESTIMATEDA target, not a fixed dateHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all ESTIMATED pins63% CONFIDENCEOverall confidence: 63%How well the pin's source and references back up its dates.Weighted average of how firmly 3 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins from 50% to 74% confidence1.5 years agoCoverage dated 4 and 7 April 2025 reports the deal as already completed; neither fetched article states the exact completion day, so it is estimated from the earlier of the two publication dates.^[1]

  Abu Dhabi's CYVN Holdings completed its acquisition of McLaren Automotive and a non-controlling stake in McLaren Racing, merging the carmaker with EV start-up Forseven under a new McLaren Group Holdings led by chief executive Nick Collins.

  0.62

  00
• Health10/04/2026@HealthDesk

  FDA Approves AbbVie's Juvmo, First D1/D5 Agonist for Parkinson's

  1 North Waukegan Road, North Chicago, Illinois, United StatesAbbVie

  

  Starts 09/25/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins83% CONFIDENCEOverall confidence: 83%How well the pin's source and references back up its dates.Weighted average of how firmly 5 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better11 days agoPharmaceutical Technology^[3] (28 Sept 2026) says that per the FDA's website tavapadon was approved on 25 September, and TIKR^[5] cites Reuters for approval 'on Friday, September 25'; AbbVie's^[1] own release is dated 28 September.

  On 25 September 2026 the FDA approved AbbVie's Juvmo (tavapadon), a once-daily tablet and the first selective D1/D5 receptor agonist approved for adults with Parkinson's disease; AbbVie announced it on 28 September.

  0.62

  00
• Business10/04/2026@EconDesk

  AbbVie Completes US$10.9 Billion Acquisition of Apogee

  1 North Waukegan Road, North Chicago, Illinois, United StatesAbbVie

  

  Starts 09/03/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins82% CONFIDENCEOverall confidence: 82%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better33 days agoAbbVie's 8-K press release is datelined 'NORTH CHICAGO, Ill., Sept. 3, 2026' and says AbbVie 'today announced that it has completed its acquisition of Apogee'.^[1]

  On 3 September 2026 AbbVie completed its acquisition of Apogee Therapeutics, paying US$135.11 per share in cash for a total equity value of about US$10.9 billion.

  $10.9B

  0.62

  00